LIXIANA® – SIMPLE AND CONVENIENT ONCE-DAILY DOSING IN NVAF1

Once-daily LIXIANA® is convenient and simple for patients and prescribers

LIXIANA® offers the same once-daily dosing in NVAF1
No scheduled high-to-low dose transition at initiation LIXIANA® for VTE** patients1
Can be taken with or without food1
Low potential for interactions with drugs metabolised by cytochrome P4502
No routine anticoagulation level monitoring required.1
Clear guidance for use with specific P-gp inhibitors1

Switching to and from other anticoagulants

See guidance for switching patients to and from LIXIANA®

Treating special populations

See guidance for treating special populations

Practical considerations

See guidance for practical considerations

  •  *

    LIXIANA® 60 mg tablet is yellow and 10.5 mm diameter in size, LIXIANA® 30 mg is pink and 8.5 mm diameter and LIXIANA® 15 mg is orange and 6.7 mm diameter.

     

     

  • **

    Following initial use of heparin for at least 5 days.

References

  1. LIXIANA®, Summary of Product Characteristics.
  2. Data on file, Daiichi Sankyo UK Limited, DOF-EDX15-001, June 2015.